ABBV – AbbVie Inc.
ABBV — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
1.31
Margin Of Safety %
2
Put/Call OI Ratio
0.83
EPS Next Q Diff
2.93
EPS Last/This Y
11.88
EPS This/Next Y
1.99
Price
227.68
Target Price
253.85
Analyst Recom
1.67
Performance Q
3.63
Upside
-80.4%
Beta
0.3
Ticker: ABBV
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-05-18 | ABBV | 209.43 | 1.00 | 0.51 | 219885 |
| 2026-05-19 | ABBV | 213.86 | 0.98 | 0.33 | 225964 |
| 2026-05-20 | ABBV | 212.28 | 0.95 | 0.60 | 235039 |
| 2026-05-21 | ABBV | 214.58 | 0.96 | 0.15 | 237705 |
| 2026-05-22 | ABBV | 215.74 | 0.92 | 0.42 | 243981 |
| 2026-05-26 | ABBV | 213.11 | 0.95 | 0.51 | 237391 |
| 2026-05-27 | ABBV | 215.44 | 0.94 | 0.71 | 241450 |
| 2026-05-28 | ABBV | 218.28 | 0.94 | 0.26 | 244752 |
| 2026-05-29 | ABBV | 217.59 | 0.92 | 0.70 | 248457 |
| 2026-06-02 | ABBV | 215.43 | 0.94 | 0.16 | 244509 |
| 2026-06-03 | ABBV | 217.13 | 0.91 | 0.24 | 250380 |
| 2026-06-04 | ABBV | 224.94 | 0.92 | 0.38 | 250211 |
| 2026-06-05 | ABBV | 227.24 | 0.91 | 0.54 | 252474 |
| 2026-06-08 | ABBV | 222.94 | 0.92 | 0.24 | 247010 |
| 2026-06-09 | ABBV | 225.35 | 0.84 | 0.72 | 265050 |
| 2026-06-10 | ABBV | 224.96 | 0.84 | 0.21 | 267845 |
| 2026-06-11 | ABBV | 224.77 | 0.83 | 0.55 | 271434 |
| 2026-06-12 | ABBV | 227.66 | 0.83 | 0.43 | 273086 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-05-18 | ABBV | 209.46 | 26.8 | 18577.5 | 14.24 |
| 2026-05-19 | ABBV | 213.89 | 26.8 | 19179.5 | 14.24 |
| 2026-05-20 | ABBV | 212.33 | 26.8 | 18523.6 | 14.24 |
| 2026-05-21 | ABBV | 214.57 | 26.8 | 18933.0 | 14.24 |
| 2026-05-22 | ABBV | 215.70 | 26.8 | 18813.5 | 14.24 |
| 2026-05-26 | ABBV | 213.11 | 26.8 | 18397.7 | 14.24 |
| 2026-05-27 | ABBV | 215.41 | 26.8 | 18935.0 | 14.24 |
| 2026-05-28 | ABBV | 218.65 | 26.8 | 19037.5 | 14.24 |
| 2026-05-29 | ABBV | 217.65 | 26.8 | 18574.0 | 14.24 |
| 2026-06-01 | ABBV | 212.95 | 26.8 | 18163.1 | 14.24 |
| 2026-06-02 | ABBV | 215.64 | 26.8 | 18980.5 | 14.24 |
| 2026-06-03 | ABBV | 217.14 | 26.8 | 18872.4 | 14.24 |
| 2026-06-04 | ABBV | 224.88 | 26.8 | 19524.3 | 14.24 |
| 2026-06-05 | ABBV | 227.24 | 26.8 | 18924.5 | 14.24 |
| 2026-06-08 | ABBV | 222.95 | 26.8 | 18233.1 | 14.24 |
| 2026-06-09 | ABBV | 225.38 | 26.9 | 18947.0 | 14.25 |
| 2026-06-10 | ABBV | 225.02 | 26.9 | 18658.8 | 14.25 |
| 2026-06-11 | ABBV | 224.76 | 26.9 | 18680.9 | 14.25 |
| 2026-06-12 | ABBV | 227.68 | 26.8 | 19009.4 | 14.25 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-05-18 | ABBV | -1.98 | 1.84 | 1.19 |
| 2026-05-19 | ABBV | -1.72 | 1.84 | 1.19 |
| 2026-05-20 | ABBV | -1.98 | 1.84 | 1.18 |
| 2026-05-21 | ABBV | -1.98 | 1.84 | 1.18 |
| 2026-05-22 | ABBV | -1.98 | 1.84 | 1.18 |
| 2026-05-26 | ABBV | -1.98 | 0.39 | 1.18 |
| 2026-05-27 | ABBV | -2.14 | 0.39 | 1.18 |
| 2026-05-28 | ABBV | -2.14 | 0.39 | 1.28 |
| 2026-05-29 | ABBV | -2.14 | 0.39 | 1.28 |
| 2026-06-02 | ABBV | -2.14 | -0.17 | 1.28 |
| 2026-06-03 | ABBV | -2.14 | -0.17 | 1.28 |
| 2026-06-04 | ABBV | -2.14 | -0.17 | 1.28 |
| 2026-06-05 | ABBV | -2.14 | -0.17 | 1.28 |
| 2026-06-08 | ABBV | -2.14 | -0.26 | 1.28 |
| 2026-06-09 | ABBV | -2.14 | -0.26 | 1.28 |
| 2026-06-10 | ABBV | -2.14 | -0.26 | 1.31 |
| 2026-06-11 | ABBV | -2.14 | -0.26 | 1.31 |
| 2026-06-12 | ABBV | -2.14 | -0.26 | 1.31 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.92
Avg. EPS Est. Current Quarter
3.77
Avg. EPS Est. Next Quarter
3.85
Insider Transactions
-2.14
Institutional Transactions
-0.26
Beta
0.3
Average Sales Estimate Current Quarter
16760
Average Sales Estimate Next Quarter
17318
Fair Value
232.26
Quality Score
69
Growth Score
85
Sentiment Score
78
Actual DrawDown %
7
Max Drawdown 5-Year %
-21.9
Target Price
253.85
P/E
112.29
Forward P/E
13.98
PEG
0.65
P/S
6.4
P/B
P/Free Cash Flow
20.13
EPS
2.03
Average EPS Est. Cur. Y
14.25
EPS Next Y. (Est.)
16.24
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
5.72
Relative Volume
0.62
Return on Equity vs Sector %
-81.6
Return on Equity vs Industry %
-92
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
19009.4
◆
ABBV
Healthcare
$227.66
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
66
Range 1M
86.5%
Sup Dist
1.9%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
42.7%
EPS NY
14.2%
52W%
71.7%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+31.4% upside
Upside
+31.4%
Quality
69
MoS
2%
AbbVie Inc.Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 57000
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
ABBV
Latest News
—
Caricamento notizie per ABBV…
stock quote shares ABBV – AbbVie Inc. Stock Price stock today
news today ABBV – AbbVie Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ABBV – AbbVie Inc. yahoo finance google finance
stock history ABBV – AbbVie Inc. invest stock market
stock prices ABBV premarket after hours
ticker ABBV fair value insiders trading